Welcome

to our investor hub

We aim to foster a transparent, continuous and trusting dialogue with all capital market participants.

to our investor hub

Q3/2022 Trading Update

The Zur Rose Group performed in line with revenue expectations in the third quarter of 2022 and will see EBITDA at the upper end of the forecast target range for 2022.

Read more Read more

Newsroom

Our newsroom provides you with the latest corporate news and ad hoc press releases. 

Read more Read more

Our company presentation

Get the latest information on market trends, financials and the strategy of the Zur Rose Group. 

Read more Read more

Online Annual Report 2021

The Zur Rose Group continued to rigorously pursue its growth strategy in 2021 – in particular seizing the opportunities arising from electronic prescriptions in Germany and internationalisation. 

Read more Read more

Capital Markets Day 2021

Discover the presentation of our most recent Capital Markets Day. 

Read more Read more

Sustainability Report 2021

In our first sustainability report, we disclose current and future trends. This transparency helps us to appreciate our strengths and to identify room for improvement. 

Read more Read more

Our investment highlights

The Zur Rose Group is ideally positioned to deliver on the eRx (​​e-prescription) opportunity in Germany and execute its strategy to build the digital healthcare ecosystem of choice. 

Read more Read more

Financial publications

Here you can find all financial publications of the Zur Rose Group. 

Read more Read more

Financial calendar

Our financial calendar gives you an overview of communication dates, investor conferences, roadshows and the annual general meeting. 

Read more Read more

Questions?

Want to know more? Our Investor Relations team will be glad to answer any questions you may have about the Zur Rose Group share and related capital market topics.

Additional contacts can be found here:

Dr. Daniel Grigat
Head of Investor Relations